Exocytosis is a vesicle fusion process driven by
soluble N-ethylmaleimide-sensitive factor attachment protein receptors (
SNAREs). A classic exocytic pathway is
insulin-stimulated translocation of the
glucose transporter type 4 (GLUT4) from intracellular vesicles to the plasma membrane in adipocytes and skeletal muscles. The GLUT4 exocytic pathway plays a central role in maintaining
blood glucose homeostasis and is compromised in
insulin resistance and
type 2 diabetes. A candidate regulator of GLUT4 exocytosis is tomosyn, a soluble
protein expressed in adipocytes. Tomosyn directly binds to GLUT4 exocytic
SNAREs in vitro but its role in GLUT4 exocytosis was unknown. In this work, we used CRISPR-Cas9 genome editing to delete the two tomosyn-encoding genes in adipocytes. We observed that both basal and
insulin-stimulated GLUT4 exocytosis was markedly elevated in the double knockout (DKO) cells. By contrast, adipocyte differentiation and
insulin signaling remained intact in the DKO adipocytes. In a reconstituted
liposome fusion assay, tomosyn inhibited all the SNARE complexes underlying GLUT4 exocytosis. The inhibitory activity of tomosyn was relieved by NSF and α-SNAP, which act in concert to remove tomosyn from GLUT4 exocytic
SNAREs. Together, these studies revealed an inhibitory role for tomosyn in
insulin-stimulated GLUT4 exocytosis in adipocytes. We suggest that tomosyn-arrested
SNAREs represent a reservoir of fusion capacity that could be harnessed to treat patients with
insulin resistance and
type 2 diabetes.